A new antiviral treatment against genital herpes has shown better performance than other available treatments. Pritelivir, a new antiviral treatment produced by a leading pharmaceutical company AiCurius, has passed the phase II trial.
This company has been researching and developing treatments for infectious disease and focuses exclusively on the research of novel antivirus and its cure. The drug Pritelivir has not only completed a Phase II trial in which its performance was better than the current drugs used for the treatment of genital herpes but when it was compared with another drug Valacyclovir, it showed much more improvement than that drug. It had minimized the virus shedding, pain, and also there were lesser genital lesions in the patients.
This drug mostly focuses on the molecular level, and due to this reason, it can minimize the effect of the virus. Pritelivir is different than other regular antiviral drugs as they had nucleoside analogs that stopped copying the process of new viral DNA. Still, it rather focuses on preventing the whole process by inhibiting the helicase primase complex, which opens the DNA chain, which has to be copied. Not only that, it does not require activation within the infected cell and can protect the uninfected cells as well.
From these results, it was concluded that Pritelivir could also be useful for patients who have an impaired immune system with the herpes simplex virus (HSV) strains that are usually resistant to nucleoside analogs. The CEO of AiCuris has said that they are planning to start the trial session in the patients very soon.
This Europe based company may have a strong competition with Genocea, which is a US-based company that has completed a Phase II trial of a new drug, which is also immunotherapy that fights against the HSV virus. But AiCuris do not have any such competition within the country.
The drug Pritelivir targets the HSV-1 and HSV-2 virus that makes it effective against both cold sores and genital herpes, respectively. The company has started to evaluate the suitable patients for the Phase II trial and will soon run the tests even for cold sores.
Not only that, this company is now developing a therapy for hepatitis B. It has recently licensed an antiviral drug that fights against human cytomegalovirus (CMV) to MSD in a record deal.
This German-based biotech company seems to be determined to make a difference in the lives of millions of lives with infectious diseases. On top of that, AiCuris has also entered clinical trial phases with a new antibiotic drug, which helps in the treatment of multi-resistant bacterial infections (superbugs).